{"id":425834,"date":"2026-05-05T03:24:07","date_gmt":"2026-05-05T03:24:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/425834\/"},"modified":"2026-05-05T03:24:07","modified_gmt":"2026-05-05T03:24:07","slug":"two-asx-healthcare-shares-that-could-triple-in-the-next-year","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/425834\/","title":{"rendered":"Two ASX healthcare shares that could triple in the next year"},"content":{"rendered":"\n

As more quarterly reports roll in, brokers<\/a> are quickly adjusting their outlooks on plenty of ASX shares.\u00a0<\/p>\n

Two AS healthcare shares that just received fresh guidance from the team at Morgans are Epiminder Ltd (ASX: EPI<\/a>) and Saluda Medical Inc (ASX: SLD<\/a>).\u00a0<\/p>\n

Both of these ASX healthcare shares have fallen significantly in 2026, down between 48% and 60%.\u00a0<\/p>\n

However the team at Morgans is anticipating a bounce back for both.\u00a0<\/p>\n

Here is what the broker had to say.\u00a0<\/p>\n

\"A<\/p>\n

Image source: Getty Images<\/p>\n

Epiminder develops the Minder system, a technology currently under evaluation that aims to improve epilepsy treatment by continuously recording brain activity data to reveal previously unseen epileptic episodes.<\/p>\n

In 2026, the ASX healthcare stock has fallen nearly 50%.\u00a0<\/p>\n

However following its recent quarterly activities report,<\/a> the team at Morgans has reiterated its speculative buy recommendation.\u00a0<\/p>\n

The broker said momentum is building, with 3QFY26 activity highlights improving execution. Morgans also highlighted DETECT enrolment<\/a> and site activation now gaining traction following a slow start.<\/p>\n

Since 1HFY26, EPI has expanded to 18 Tier-1 US centres and increased enrolled patients to 15 (from 3 in February), remaining on track to reach 25 this month. Cash burn was lower than expected, reflecting timing of site invoicing, while runway remains intact through CY28. We adjusted FY26-28 forecasts and lowered our DCF-based target price to A$2.23 mainly on risk-free rate adjustment.<\/p>\n

Yesterday, Epiminder shares closed trading at 54 cents per share.\u00a0<\/p>\n

From this price, the updated target from Morgans indicates an upside potential of more than 300%.\u00a0<\/p>\n

Saluda Medical Inc (ASX: SLD<\/a>) <\/p>\n

Saluda Medical is an ASX healthcare commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform.<\/p>\n

Its share price is down nearly 60% year to date.\u00a0<\/p>\n

However a fresh price target from Morgans indicates this could rebound significantly.\u00a0\u00a0<\/p>\n

The company also released a quarterly report last week.\u00a0<\/a><\/p>\n

Morgans said the 3QFY26 activity continued to build on strong 1H performance, with accelerating US commercial momentum underpinning another revenue upgrade.\u00a0<\/p>\n

The broker highlighted revenue growth of 13% QoQ to US$23.8m (+34% YoY), supported by strong growth in implanted patients (+55% YoY), active physicians and utilisation.\u00a0<\/p>\n

We view the second consecutive guidance upgrade (now US$87m, +24% YoY) as evidence of improving visibility, with salesforce scaling and physician productivity continuing to trend ahead of expectations. We update FY26 forecasts in line with guidance, with our DCF-based target price lowered to A$2.94, mainly on FX and risk-free rate adjustments. SPECULATIVE BUY maintained.<\/p>\n

This updated price target of $2.94 indicates an upside potential of 400%.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"As more quarterly reports roll in, brokers are quickly adjusting their outlooks on plenty of ASX shares.\u00a0 Two…\n","protected":false},"author":2,"featured_media":425835,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[163,521,85,46],"class_list":["post-425834","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-health","tag-healthcare","tag-il","tag-israel"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/425834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=425834"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/425834\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/425835"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=425834"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=425834"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=425834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}